Compare BOH & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOH | IDYA |
|---|---|---|
| Founded | 1897 | 2015 |
| Country | United States | United States |
| Employees | 1877 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.5B |
| IPO Year | N/A | 2019 |
| Metric | BOH | IDYA |
|---|---|---|
| Price | $84.86 | $36.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 16 |
| Target Price | ★ $85.40 | $52.86 |
| AVG Volume (30 Days) | 378.7K | ★ 1.4M |
| Earning Date | 04-20-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.62% | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $218,710,000.00 |
| Revenue This Year | $15.66 | N/A |
| Revenue Next Year | $7.82 | $201.05 |
| P/E Ratio | $17.08 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $59.36 | $21.33 |
| 52 Week High | $86.31 | $40.58 |
| Indicator | BOH | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 63.03 | 55.30 |
| Support Level | $75.65 | $29.51 |
| Resistance Level | N/A | $38.17 |
| Average True Range (ATR) | 1.73 | 1.56 |
| MACD | 0.18 | -0.40 |
| Stochastic Oscillator | 72.70 | 24.74 |
Bank of Hawaii Corp provides a broad range of financial products and services predominantly to customers in Hawaii, Guam, and other Pacific Islands. The Bank's subsidiaries are engaged in equipment leasing, securities brokerage, investment advisory services, and providing credit insurance. It is organized into three business segments for management reporting purposes: Consumer Banking, Commercial Banking, and Treasury and Other. Majority of the revenue is generated from Consumer Banking segment which offers a broad range of financial products and services, including loan, deposit and insurance products; private banking and international client banking services; trust services; investment management; and institutional investment advisory services.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.